highperformr logo

Biocartis's Overview

Total employees304
HeadquartersMechelen
Founded2007

Biocartis is an innovative molecular diagnostics (MDx) company committed to revolutionizing molecular testing with its unique and proprietary Idylla™ platform. The Idylla™ platform is a fully automated, real-time PCR based system designed to offer fast, convenient, and accurate molecular diagnostic results. Biocartis focuses on providing diagnostic solutions in oncology and infectious diseases, enabling personalized medicine and improving patient outcomes. Their technology aims to make complex molecular testing accessible to labs of all sizes, from small to large.

Where is Biocartis's Headquarters?

HQ Function

The Mechelen headquarters serves as the central hub for Biocartis's global operations, including corporate management, research and development (R&D), manufacturing of the Idylla™ instruments and cartridges, warehousing, and global commercial operations.

Notable Features:

The facility houses state-of-the-art laboratories, advanced manufacturing units for its Idylla™ platform, and modern office spaces designed to foster collaboration and innovation. It is equipped for the entire product lifecycle from research to production and distribution.

Work Culture:

Biocartis fosters a dynamic, innovative, and collaborative work culture. Employees are driven by a shared mission to transform molecular diagnostics and improve patient care, with a strong emphasis on scientific excellence, agility, and teamwork.

HQ Significance:

The Mechelen headquarters is critical to Biocartis's mission, being the birthplace of the Idylla™ technology and the core site for its development, production, and strategic global management. Its location provides access to a strong talent pool and logistics network.

Values Reflected in HQ: The headquarters reflects Biocartis's core values of innovation, precision, and commitment to quality, evident in its advanced research and manufacturing capabilities, quality control systems, and collaborative workspaces designed to accelerate development.

Location:

Biocartis supports a wide range of functions globally, with its Idylla™ platform and tests distributed in over 70 countries. This is achieved through a direct sales force in key markets (e.g., Europe, US) and an extensive network of distribution partners in other regions. Global functions include sales and marketing, technical and customer support, logistics and supply chain management, R&D collaborations, and engagement in clinical studies to expand test applications and market access worldwide.

Street Address:

Generaal de Wittelaan 11B

City:

Mechelen

State/Province:

Antwerp

Country:

Belgium

Biocartis's Global Presence

Little Falls, New Jersey, USA

Address: 150 Clove Road, 11th Floor, Suite 1102, Little Falls, NJ 07424, USA

To drive market penetration and growth for the Idylla™ platform in the United States and North America by providing localized expertise, regulatory engagement, customer support, and strategic partnerships with healthcare providers and laboratories.

Buying Intent Signals for Biocartis

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Biocartis

As of April 2025, Biocartis' leadership includes:

Roger Moody - Chief Executive Officer
Piet Houwen - Chief Financial Officer
Dr. Anthony L. Johnson - Chief Commercial Officer
Dr. Gert Malfliet - Chief Operating Officer
Angelo De Rosa - Chief People & Sustainability Officer
Dr. Dalena L.D. McKay - Chief Medical Officer
Koenraad van der Knaap - General Counsel

Investors of Biocartis

Biocartis has been backed by several prominent investors over the years, including:

Invesco Ltd.
Johnson & Johnson Innovation - JJDC, Inc.
Korys Investments NV
Biocartis is publicly traded on Euronext Brussels (BCART), with various institutional and retail investors.

Executive New Hires/Exits in the Last 12 Months

Hire1
Exits1

In the past 12 months, Biocartis experienced a significant transition in its financial leadership, with the departure of its Chief Financial Officer, Jean-Pascal Viola, and the subsequent appointment of Piet Houwen as the new CFO to guide the company's financial strategy and operations.

Departures

Jean-Pascal Viola, Jean-Pascal Viola departed from his role as Chief Financial Officer.

New Appointments:

Piet Houwen, Piet Houwen appointed as new Chief Financial Officer, succeeding Jean-Pascal Viola.

Technology (Tech Stack) used by Biocartis

Discover the tools Biocartis uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Biocartis Email Formats and Examples

Biocartis commonly uses email formats such as [first_initial][last]@biocartis.com (e.g., jdoe@biocartis.com) or [first].[last]@biocartis.com (e.g. jane.doe@biocartis.com). Understanding these patterns can be useful for professional communication when trying to reach Biocartis employees.

[first_initial][last]@biocartis.com

Format

rmoody@biocartis.com

Example

80%

Success rate

News and media

GlobeNewswireMay 16, 2024

Biocartis Q1 2024 Business Update

Biocartis reported its Q1 2024 financial results and business highlights, detailing commercial cartridge volume, revenue trends, and progress on its strategic objectives, including menu expansion for its Idylla™ platform and ongoing market penetration efforts....more

GlobeNewswireApril 25, 2024

Biocartis Announces FDA 510(k) Submission for its Idylla™ MSI Test

Biocartis submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its Idylla™ MSI Test. This submission aims to make the rapid and easy-to-use test for microsatellite instability available for colorectal cancer patients in the U.S....more

GlobeNewswireMarch 14, 2024

Biocartis Expands Idylla™ Test Menu in Japan with IDH1-2 Test for Acute Myeloid Leukemia

Biocartis announced the launch of its Idylla™ IDH1-2 Mutation Assay Kit (RUO - Research Use Only) in Japan. This expansion of its oncology test menu aims to support the diagnosis and research of Acute Myeloid Leukemia (AML) in this key Asia-Pacific market....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Biocartis, are just a search away.